"Phenylthiohydantoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Thiohydantoin benzene derivative.
| Descriptor ID |
D010669
|
| MeSH Number(s) |
D03.383.129.308.432.555.868.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phenylthiohydantoin".
Below are MeSH descriptors whose meaning is more specific than "Phenylthiohydantoin".
This graph shows the total number of publications written about "Phenylthiohydantoin" by people in this website by year, and whether "Phenylthiohydantoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 2 | 4 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 6 | 7 |
| 2024 | 4 | 0 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phenylthiohydantoin" by people in Profiles.
-
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study. Clin Cancer Res. 2026 May 15; 32(10):1973-1982.
-
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol. 2026 May; 89(5):396-403.
-
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer. Clin Transl Sci. 2025 12; 18(12):e70425.
-
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e258751.
-
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 06; 13(12):e7334.
-
Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2024 04 02; 23(4):552-563.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 03 15; 30(6):1152-1159.
-
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and =75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol. 2024 Aug; 7(4):860-869.
-
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response. Proc Natl Acad Sci U S A. 2023 07 25; 120(30):e2221809120.